Assembly Biosciences (STU:V7B) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 11, 2026)


STU:V7B Assembly Biosciences Inc STU:V7B
31 GF Score
Price €24.00
GF Value €17.38
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Assembly Biosciences Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Assembly Biosciences's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

STU:V7B vs CTNM, PRTA, RGNX: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Assembly Biosciences's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Assembly Biosciences Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's Margin of Safety % (DCF Earnings Based) falls into.


STU:V7B
31GF Score
Assembly Biosciences Inc STU:V7B
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Assembly Biosciences (STU:V7B) Overvalued in 2026?

Based on GuruFocus' analysis, Assembly Biosciences stock appears to be overvalued. The current stock price of €24.00 is trading 38.1% above its estimated GF Value™ of €17.38. GuruFocus considers Assembly Biosciences to be Significantly Overvalued.

Key valuation signals for STU:V7B:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €17.38 vs. price of €24.00 (38.1% above fair value)
  • GF Score™: 31/100 with 3 warning signs

No single metric tells the full story. See the STU:V7B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Assembly Biosciences Business Description

Other Exchanges ASMB:USA
Address Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
31GF Score

Get the complete analysis for STU:V7B

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€24.00
Price
€17.38
GF Value